Provenienza dei contatti di primo grado di Thomas Blankenstein
Entità | Tipo di entità | Settore Industriale | |
---|---|---|---|
T-Knife GmbH
T-Knife GmbH BiotechnologyHealth Technology T-Knife GmbH operates as an next-generation adoptive T-cell company using its proprietary humanized T-cell receptor mouse platform to treat solid tumors. The company was founded by Thomas Blankenstein, Elisa Kieback and Holger Specht in 2018 and is headquartered in Berlin, Germany.
8
| Holding Company | Biotechnology | 8 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Thomas Blankenstein tramite i suoi contatti personali
Società | Settore | Persone collegate | Posizione principale |
---|---|---|---|
University of Southern California
University of Southern California Other Consumer ServicesConsumer Services University of Southern California is a private research university that mainly offers undergraduate, graduate & other higher education. The university was founded in 1880 and is headquartered in Los Angeles, CA. | College/University | Undergraduate Degree | |
Rinri Therapeutics Ltd.
Rinri Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Rinri Therapeutics Ltd. operates as a biotechnology company developing a novel cell-based therapy to restore hearing. The company was founded in 2018 and is headquartered in Sheffield, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
EQT Partners GmbH | Investment Managers | Private Equity Investor | |
Cardior Pharmaceuticals GmbH
Cardior Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Cardior Pharmaceuticals GmbH develops, manufactures and wholesales drugs. It focuses on the discovery, development and clinical validation of noncoding RNA therapeutics targeting microRNAs as medicines for patients with various forms of heart failure. The company was founded by Sandor Batkai, Claudia Ulbrich, and Thomas Thum on July 21, 2016 and is headquartered in Hannover, Germany. | Pharmaceuticals: Major | Director/Board Member | |
LSP Services Deutschland GmbH | Investment Managers | Private Equity Analyst | |
NBE-Therapeutics AG
NBE-Therapeutics AG BiotechnologyHealth Technology NBE-Therapeutics AG operates as biotechnology company. It develops next-generation ADCs improving treatment options for cancer patients. The company was founded by Ulf Grawunder in 2012 and is based in Basel, Swizerland. | Biotechnology | Director/Board Member | |
Topas Therapeutics GmbH
Topas Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Topas Therapeutics GmbH engages in pharmaceutical preparations. The company is headquartered in Hamburg, Germany. | Pharmaceuticals: Major | Chairman | |
TACALYX GmbH
TACALYX GmbH Miscellaneous Commercial ServicesCommercial Services TACALYX GmbH engages in the discovery and development of Tumor Associated Carbohydrate Antigenantibodies to treat cancer. The company was founded by Peter Sondermann, Peter H. Seeberger, and Oren Moscovitz and is headquartered in Berlin, Germany. | Miscellaneous Commercial Services | Director/Board Member | |
Boehringer Ingelheim (Venture Capital)
Boehringer Ingelheim (Venture Capital) Investment ManagersFinance Boehringer Ingelheim (BIVF) is the venture capital arm of Boehringer Ingelheim International GmbH, itself a subsidiary of C.H. Boehringer Sohn AG & Co. KG. The firm was founded in 2010 and is headquartered in Ingelheim, Germany. It also has two US offices located in Fremont, California, and Cambridge, Massachusetts. | Investment Managers | Private Equity Investor | |
Berlin Institute of Health | Consultant / Advisor | ||
Aelin Therapeutics NV
Aelin Therapeutics NV Pharmaceuticals: MajorHealth Technology Aelin Therapeutics NV develops drugs for antibiotics and first-in-class therapeutics. The company is based in Leuven, Belgium. The Belgian company was founded in 2017. The CEO is Els Beirnaert. | Pharmaceuticals: Major | Director/Board Member | |
Rgenta Therapeutics, Inc.
Rgenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Rgenta Therapeutics, Inc. manufactures medicines for oncology and neurological disorders. The company was founded by Simon Xi, Travis Wager, and Zhiping Weng and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Chairman | |
Monopteros Therapeutics, Inc.
Monopteros Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Monopteros Therapeutics, Inc. manufactures pharmaceuticals. | Pharmaceuticals: Major | Director/Board Member | |
Imcheck Therapeutics SAS
Imcheck Therapeutics SAS Pharmaceuticals: MajorHealth Technology Imcheck Therapeutics SAS operates as a biopharmaceutical company which develops immunotherapeutic anti-cancer strategies for research. The company was founded by Olive Daniel in 2015 and is headquartered in Marseille, France. | Pharmaceuticals: Major | Chairman | |
Partner Therapeutics, Inc.
Partner Therapeutics, Inc. BiotechnologyHealth Technology Partner Therapeutics, Inc. develops and commercializes therapeutics that improves health and economic outcomes in the treatment of cancer. Its development focus spans the entire range of cancer therapy from primary treatments to supportive care. The company is headquartered in Boston, MA. | Biotechnology | Founder | |
GlaxoSmithKline LLC
GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology GlaxoSmithKline LLC engages in discovering, developing, and delivering medicines, vaccines, and other healthcare products. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. It also provides vaccines for children and adults; and over-the-counter products. The company was founded in 1929 and is headquartered in Philadelphia, PA. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Nirvan Consultants LLC | President | ||
Merck Research Ventures
Merck Research Ventures Investment ManagersFinance Merck Research Ventures, a subsidiary of Merck Research Laboratories is a venture capital firm founded in 2000. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Private Equity Investor | |
Arcum Therapeutics, Inc.
Arcum Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Arcum Therapeutics, Inc. develops pharmaceutical drug products. It provides technologies aim at therapeutic intervention of multidrug-resistant bacterial infections. The company was founded by Paul M. Dunman and is headquartered in Pittsford, NY. | Pharmaceuticals: Major | Director/Board Member | |
RA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
MONTE ROSA THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
Vertical Bio AG
Vertical Bio AG BiotechnologyHealth Technology Part of Pierre Fabre Participations SAS, Vertical Bio AG is a Swiss company that develops novel cancer therapies. The company is based in Basel, Switzerland. Vertical Bio was acquired by Pierre Fabre SA on September 12, 2023. | Biotechnology | Chairman | |
Launchpad Therapeutics, Inc.
Launchpad Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Launchpad Therapeutics, Inc. develops novel therapeutics. | Miscellaneous Commercial Services | President | |
Cimeio Therapeutics AG
Cimeio Therapeutics AG Packaged SoftwareTechnology Services Cimeio Therapeutics AG is an applied gene editing and immunotherapy company based in Basel, Switzerland. Cimeio is developing a portfolio of shielded-cell & immunotherapy pairs™ (scip) that have the potential to transform hematopoietic stem cell transplant. The Swiss company's technology platform is based on the design and expression of modified variants of naturally occurring cell surface proteins in hscs. These novel variants maintain their function but are resistant to depletion when targeted by a paired immunotherapy which has high affinity for the wild-type version of these proteins. Cimeio is the leader of the field of epitope editing and is developing a portfolio of shielded-cell & immunotherapy pairs™ (scip), novel immunotherapies which have the potential to transform treatment of hematologic diseases. The company develops state-of-the-art immunotherapies, along with paired, modified variants of naturally occurring cell surface proteins in hscs. These immunotherapies have significant therapeutic potential, which Cimeio is using to develop curative treatments for patients with hematologic malignancies, autoimmune disorders, and genetic diseases. The company was founded by Lukas Jeker and the CEO is Thomas Fuchs. | Packaged Software | Director/Board Member | |
Bright Peak Therapeutics, Inc.
Bright Peak Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Bright Peak Therapeutics AG, Bright Peak Therapeutics, Inc. develops immunotherapies for the treatment of cancer and autoimmune diseases. The company is based in San Diego, CA. The company was founded by Vijaya R. Pattabiraman, Jeffrey Bode. The CEO is Fredrik Wiklund. | Pharmaceuticals: Major | Director/Board Member | |
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | Investment Managers | Corporate Officer/Principal | |
Bright Peak Therapeutics AG
Bright Peak Therapeutics AG BiotechnologyHealth Technology Bright Peak Therapeutics AG engages in the development of engineered cytokines for immuno-oncology indications. The company is headquartered in Basel, Switzerland. | Biotechnology | Director/Board Member | |
University of Oxford | College/University | Doctorate Degree | |
Universität Ulm | College/University | Doctorate Degree | |
Imperial College London | College/University | Undergraduate Degree | |
ROCHE HOLDING AG | Pharmaceuticals: Major | Corporate Officer/Principal | |
Ridgeline Therapeutics | Chief Tech/Sci/R&D Officer | ||
BLACK DIAMOND THERAPEUTICS, INC. | Biotechnology | Chief Tech/Sci/R&D Officer | |
Enterprise Therapeutics Ltd.
Enterprise Therapeutics Ltd. BiotechnologyHealth Technology Enterprise Therapeutics Ltd. operates as a drug discovery company that engages in the research and development of therapies for the treatment of respiratory diseases. It focuses on developing therapies for chronic obstructive pulmonary diseases, cystic fibrosis, and asthma. The company was founded by John Mervyn David Store in May 2014 and is headquartered in Falmer, the United Kingdom. | Biotechnology | Director/Board Member | |
Monte Rosa Therapeutics AG
Monte Rosa Therapeutics AG Pharmaceuticals: MajorHealth Technology Monte Rosa Therapeutics AG develops, manufactures and distributes cancer drugs that modulate protein degradation pathways. The company was founded in 2018 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Director/Board Member | |
Versant Ventures (Switzerland) GmbH | Investment Managers | Private Equity Investor | |
CELYAD ONCOLOGY SA | Biotechnology | Director/Board Member | |
LYTIX BIOPHARMA | Pharmaceuticals: Major | Director/Board Member | |
Georgetown University | College/University | Masters Business Admin | |
THIRD HARMONIC BIO, INC. | Pharmaceuticals: Major | Director/Board Member | |
Sapiens Steering Brain Stimulation BV
Sapiens Steering Brain Stimulation BV Electronic Equipment/InstrumentsElectronic Technology Sapiens Steering Brain Stimulation BV develops medical devices. The company was founded by Sjaak Deckers in 2011 and is headquartered in Eindhoven, the Netherlands. | Electronic Equipment/Instruments | Director/Board Member | |
JenaValve Technology GmbH
JenaValve Technology GmbH Medical SpecialtiesHealth Technology JenaValve Technology GmbH develops and manufactures transcatheter valve implantation systems for transapical and transfemoral implantation. The firm offers a therapeutic alternative to surgical aortic valve replacement for high-risk patients suffering from aortic heart valve stenosis. The company was founded by Markus Ferrari, Volker Guyenot and Hans-Reiner Figulla in 2006 and is headquartered in Munich, Germany. | Medical Specialties | Director/Board Member | |
Andera Partners SCA
Andera Partners SCA Investment ManagersFinance Andera Partners SCA (Andera Partners) is a private equity firm founded in 2001 by Pierre-Michel Passy. The firm is headquartered in Paris, France. | Investment Managers | Private Equity Investor | |
T-Knife Therapeutics, Inc. | Chief Executive Officer | ||
VIVORYON THERAPEUTICS N.V. | Biotechnology | Director/Board Member | |
SATSUMA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member |
Statistiche
Distribuzione geografica
Stati Uniti | 22 |
Germania | 11 |
Svizzera | 9 |
Regno Unito | 5 |
Francia | 4 |
Settori
Health Technology | 30 |
Finance | 8 |
Consumer Services | 6 |
Commercial Services | 4 |
Technology Services | 2 |
Posizioni
Director/Board Member | 44 |
Corporate Officer/Principal | 9 |
Chief Tech/Sci/R&D Officer | 7 |
Chairman | 7 |
Independent Dir/Board Member | 5 |
Contatti più connessi
- Borsa valori
- Insiders
- Thomas Blankenstein
- Connessioni Società